References

systhiper

Системные гипертензии

Systemic Hypertension

2075-082X2542-2189

LLC «ИнтерМедсервис»

systhiper-404

Research Article

КАРДИОНЕВРОЛОГИЯ / CARDIONEUROLOGY

Значение выбора гипотензивной терапии в коррекции поражений головного мозга:от легких когнитивных нарушений до деменции

The meaning of hypertensive therapy choice in the correction of cerebral affection: from mild cognitive impairment to dementia

Шишкова

В. Н.

Shishkova

V. N.

veronika-1306@mail.ru

ГБУЗ Центр патологии речи и нейрореабилитацииРоссияCenter for Speech Pathology and NeurorehabilitationRussian Federation

2015

23122022

1215864

2022

Шишкова В.Н.

Shishkova V.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.syst-hypertension.ru/jour/article/view/404

Нарушения и болезни нервной системы занимают сегодня первое место среди причин инвалидности. Доля их в общей заболеваемости и инвалидизации растет, что вызвано глобальным ростом сосудистых заболеваний мозга - острых и хронических нарушений мозгового кровообращения. Клиническая картина хронических нарушений мозгового кровообращения, формируясь постепенно, включает в том числе и развитие когнитивных нарушений, вплоть до деменции. Плацдармом для их развития могут служить длительно существующие сердечно-сосудистые заболевания (ССЗ). Проблема формирования когнитивных нарушений у пациентов с ССЗ, особенно артериальной гипертензией (АГ), является актуальной, с учетом постоянного роста распространенности данной патологии в популяции. Возможность повлиять на состояние когнитивных функций у пациентов с АГ, используя традиционные антигипертензивные препараты - сартаны, в процессе достижения целевых значений артериального давления существует. Однако описаны дополнительные преимущества отдельных препаратов данной группы, таких как Микардис и Твинста, в коррекции развития нарушений когнитивных функций.

Disorders and neuropathy are the leading cause of disability. Their partof total morbidity and disability is increasing due to the global growth of vascular diseases of the brain: the acute and the chronic disorders of cerebral circulation. The clinical characteristics of chronic disorders of cerebral circulation have been forming gradually, and include the development of cognitive impairments, up to dementia. The base for their development can serve thelong-term cardiovascular diseases (CVD). The problem of cognitive impairments in patients with CVD, particularly with arterial hypertension (AH), is a leading one, taking into consideration the fact that these disorders are continuing to grow in the population. There is a real possibility to impact on the cognitive functions condition in patients with AH, using traditional antihypertensive drugs such assartans to achieve the target blood pressure levels. However, there is the additional benefit of special drugs in this group, such as Micardis and Twynsta, in the correction of cognitive function disorders.

когнитивные нарушенияартериальная гипертензиятелмисартанамлодипин

cognitive impairmentarterial hypertensiontelmisartanamlodipine

References1

Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005.

Elias M.F, Wolf P.A, D`Agostino R.B . et al. Untreated blood pressure level is inversely reated to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138 (6): 353-64.

Tzourio C, Dufouil C, Ducimetiere P et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53 (9): 1948-52.

Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12 (1): 33-9.

Launer L.J, Masaki K, Petrovitch H et al. The association between midlife blood pressure level and late - life cognitive function. The Honolulu - Asia Aging Study. JAMA 1995; 274 (23): 1846-51.

Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.

Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2010.

Гусев Е.И, Боголепова А.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпреcс - информ, 2013.

Petersen R.S, Smith G.E, Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.

Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183-94.

Дамулин И.В. Легкие когнитивные нарушения. Consilium Medicum. 2004; 2: 138-41.

Преображенская И.С. Легкие и умеренные когнитивные нарушения - клинические проявления, этиология, патогенез, возможности использования ноотропной терапии. Фарматека. Психиатрия/Неврология (Спецвыпуск). 2013; с. 14-8.

Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга: Эпидемиология. Основы профилактики. М.: МЕДпресс - информ, 2009.

Prince M.J, Bird A.S, Blizard R.A. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996; 312 (7034): 801-5.

Forette F, Seux M.L. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046-52.

Danlof B, Devereux R.B, Kieldsen S.E. et al. For the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.

Hanon O. Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer's. N Engl J Med 2003; 348: 1333-41.

Brown M.J, Brown J. Does angiotensin-II protect against strokes? Lancet 1986; 2 (8504): 427-9.

Fournier A et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor - blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009; 9 (9): 1413-31.

Boutitie F, Oprisiu R, Achard J.M. et al. Does the change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta - analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007; 25: 1543-53.

Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neirobiol Exp 1996; 56: 49-54.

Wright J.W, Harding J.W. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimers disease. J Renin-Angiotensin-Aldosterone Systems 2008; 9: 226-37.

Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24 (10): 2101-7.

Hernandez R.H, Armas-Hernandez M.J, Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409-14.

Mancini G.B, Miller M.E, Ward R (for the PREVENT Investigators). Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation 2000; 102: 1503-10.

Coca A. Hypertension and vascular dementia in the elderly: the potential role of antihypertensive agents. Curr Med Res Opin 2013; 29 (9): 1045-54.

Rinaldi B, Di Fillipo C, Capuano A et al. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome. Diabetes Obes Metab 2012; 14 (4): 320-8.

Billecke Scott S, Marcovitz P.A. Long - term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension. Vascular Health and Risk Management 2013; p. 95-104

Benndorf R.A, Appel D, Maas R et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50 (4): 367-71.

Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 2012; 37 (3): 319-27.

Takagi H, Mizuno Y, Yamamoto H et al. Effects of telmisartan therapy on interleukin- 6 tumor necrosis factor - alpha levels: a meta - analysis of randomized controlled trials. Hypertens Res 2013; 36 (4): 368-73.

Goyal S.N, Bharti S, Bhatia J. et al. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes Metab 2011; 13 (6): 533-41.

Шишкова В.Н. Механизмы развития сердечно - сосудистых заболеваний и сахарного диабета типа 2: роль инсулинорезистентности. Гиперинсулинемии и гипоаподипонектинемии. Вопросы коррекции. Системные гипертензии. 2014; 2: 48-53.

Mogi M, Li J.M, Tsukuda K et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-9.

Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up - regulation of brain - derived neurotrophic factor/tropomyosin - related kinase B in hippocampus of hypertensive rats. J Cardiol 2012; 60: 489-94.

Kishi T, Hirooka Y, Sunagawa К. Telmisartan improves cognitive function through the increase in neurotrophic factor and inhibition of apoptosis in hippocampus of rats with metabolic syndrome. FASEB J 2010 April (24) Meeting Abstract Suppl.: 978.26.

Washida K, Ihara M, Nishio K, Fujita Y. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator - activated receptor - gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010; 41 (8): 1798-806.

Chao-Liang Chou, Hung-I Yeh. The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer’s Disease. Acta Cardiol Sin 2014; 30: 114-8.

Kazumasa K, Haruo H, Hirofumi S. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2012; 12: 207-14.

Fogari R, Mugellini A, Zoppi A, Lazzar P. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006, 20: 177-85.

The authors declare that there are no conflicts of interest present.